The “Fibromyalgia – Pipeline Insight, 2020” report has been added to ResearchAndMarkets.com’s offering.
Fibromyalgia Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Fibromyalgia market.
A detailed picture of the Fibromyalgia pipeline landscape is provided, which includes the disease overview and Fibromyalgia treatment guidelines. The assessment part of the report embraces in-depth Fibromyalgia commercial assessment and clinical assessment of the Fibromyalgia pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fibromyalgia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Fibromyalgia with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Fibromyalgia treatment.
- Fibromyalgia key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Fibromyalgia market.
Scope of the Report
- The Fibromyalgia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Fibromyalgia across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Fibromyalgia therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
- Detailed Fibromyalgia research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Fibromyalgia.
Companies Mentioned
- Tonix Pharmaceuticals Inc.
- Aptinyx
- Syneos Health
- Teva Pharmaceutical Industries
- Healeon Medical Inc.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Globe Newswire